Analyst firms · H.C. Wainwright · RPHM
H.C. Wainwright RPHM price target and rating history
Reneo Pharmaceuticals Inc. (RPHM) · Health Care
H.C. Wainwright rates Reneo Pharmaceuticals Inc. (RPHM) Neutral with a $1.50 price target, as of its latest action on Dec 15, 2023. It has published 4 rating actions on RPHM since December 2021, including 0 upgrades and 1 downgrade.
- Current rating
- Neutral
- Price target
- $1.50
- Median target, all firms
- Too few
- Actions on RPHM
- 4
H.C. Wainwright price target on RPHM
Every H.C. Wainwright rating on RPHM
- Dec 15, 2023
- Aug 28, 2023
- Sep 19, 2022
- Dec 21, 2021
Questions about H.C. Wainwright and RPHM
- What is H.C. Wainwright's price target for RPHM?
- H.C. Wainwright's latest stated price target for Reneo Pharmaceuticals Inc. (RPHM) is $1.50, from its action on Dec 15, 2023.
- What is H.C. Wainwright's rating on RPHM?
- H.C. Wainwright rates RPHM Neutral, a neutral rating, as of Dec 15, 2023.
- When did H.C. Wainwright last change its view on RPHM?
- On Dec 15, 2023, H.C. Wainwright downgrades to Neutral from Buy, price target $30 to $1.50.
More RPHM rating histories
All H.C. Wainwright ratingsRPHM news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.